Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Apr 09, 2021

Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference

Mar 24, 2021

Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development

Mar 18, 2021

Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

Mar 04, 2021

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results

Mar 04, 2021

Fulcrum Therapeutics Announces CEO Transition

Feb 26, 2021

Fulcrum Therapeutics Recognizes Rare Disease Day 2021

Feb 26, 2021

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET

Feb 19, 2021

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

Jan 22, 2021

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jan 19, 2021

Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Investor Tools

Privacy Policy | EU Privacy Policy | Terms of use

Social Media Guidelines

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact